id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-E-2604-0008,FDA,FDA-2015-E-2604,"Letter from U.S. Patent and Trademark Office to Gilead Sciences, Inc.",Other,Letter(s),2024-02-28T05:00:00Z,2024,2,2024-02-28T05:00:00Z,,2024-02-28T14:58:14Z,,0,0,0900006486419d62
FDA-2015-E-2604-0007,FDA,FDA-2015-E-2604,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2019-01-28T05:00:00Z,2019,1,2019-01-28T05:00:00Z,,2019-01-28T14:13:12Z,,0,0,0900006483a16b45
FDA-2015-E-2604-0006,FDA,FDA-2015-E-2604,"Determination of Regulatory Review Period for Purposes of Patent
Extension; ZYDELIG—New Drug Application 205858",Notice,Determinations,2018-02-15T05:00:00Z,2018,2,2018-02-15T05:00:00Z,2018-04-17T03:59:59Z,2024-02-20T16:20:23Z,2018-03134,0,0,0900006482f35836
FDA-2015-E-2604-0005,FDA,FDA-2015-E-2604,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,List (LST),2017-06-06T04:00:00Z,2017,6,2017-06-06T04:00:00Z,,2017-06-06T13:54:20Z,,0,0,0900006482697134
FDA-2015-E-2604-0004,FDA,FDA-2015-E-2604,Letter from U.S. Patent and Trademark Office to FDA,Other,Letter(s),2016-12-23T05:00:00Z,2016,12,2016-12-23T05:00:00Z,,2016-12-23T18:11:12Z,,0,0,09000064824344cc
FDA-2015-E-2604-0003,FDA,FDA-2015-E-2604,Letter from FDA CDER to the U.S. Patent and Trademark Office,Other,Letter(s),2015-11-05T05:00:00Z,2015,11,2015-11-05T05:00:00Z,,2015-11-05T15:08:20Z,,0,0,0900006481d14464
FDA-2015-E-2604-0001,FDA,FDA-2015-E-2604,Patent Extension Application from MORRISON & FOERSTER LLP (on behalf of ICOS CORPORATION.),Other,Application,2015-07-22T04:00:00Z,2015,7,2015-07-22T04:00:00Z,,2015-07-22T16:28:04Z,,0,0,0900006481b97bb0
FDA-2015-E-2604-0002,FDA,FDA-2015-E-2604,Letter from U.S. Patent and Trademark Office,Other,Letter(s),2015-07-22T04:00:00Z,2015,7,2015-07-22T04:00:00Z,,2015-07-22T16:28:17Z,,0,0,0900006481b97bae